COMPARE · Data as of August 21, 2026
BSX vs GMED
Verdict: Side-by-side breakdown using the Bull Rankings model. BSX scored 78.1, GMED scored 79.2 — GMED leads.
Compare another set
BSX
Boston Scientific Corporation
78.1
$50.37 · $73.0B
fundamentals as of
Score gap
1.1
GMED leads
GMED
Globus Medical, Inc.
79.2
$85.67 · $11.5B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestBSX20.4x
- Fastest growthGMED+19.7%
- Strongest balance sheetGMED0.02
- Highest qualityGMED73 / 100
- Largest discount to fair valueBSX-12%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
BSX
stronger →← stronger
GMED
71
Qualityreturns · margins · balance sheet
73
88
Growthrevenue & earnings expansion
93
76
Valuevaluation vs sector peers
73
GMED is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
BSX
GMED
$3.6bB
FCF
$756mC+
+13.5%B+
Rev
+19.7%B+
0.50B
D/E
0.02A-
20.4xB+
P/E
21.9xB+
0.75A-
PEG
1.49B
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
BSX
GMED
12% below
Price vs fair valuelower is cheaper
10% below
~1%/yr
Growth the price implies10-yr FCF · lower = less priced in
~3%/yr
+12%
1-yr DCF upside
+5%
+14%
5-yr DCF upside
+11%
+16%
10-yr DCF upside
+22%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
BSX
Why this score
- Buying back stock
GMED
No notable signals flagged.
The companies
BSXBoston Scientific Corporation
Why now
Medical Devices · market cap $73.0b. Down 54% from 52-week high of $109.50 — deep drawdown territory. Revenue growing +14%, comfortably above the S&P median. PEG 0.75 — paying under fair value for the growth rate. 29 sell-side analysts rate this a Buy with a mean 1-yr target of $62.69 (implying +24% upside).
Moat
Net margin 17% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 15% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 99% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Down 54% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
GMEDGlobus Medical, Inc.
Why now
Medical Devices · market cap $11.5b. 16% off the 52-week high of $101.40. Revenue growing +20%, comfortably above the S&P median. 13 sell-side analysts rate this a Buy with a mean 1-yr target of $103.23 (implying +20% upside).
Moat
Net margin 17% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 11% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 141% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Verdict — model-derived comparison
GMED leads BSX by 1.1 points (79.2 to 78.1), its sharpest advantage coming in D/E (grade A-). A contrarian could still prefer BSX, which trades about 12% below our DCF fair value — a margin of safety the score doesn't reward. Note they play different roles — BSX screens as value, GMED screens as growth — so the model rewards different traits for each.
Our AI analyst is busy right now, so this verdict is drawn directly from the pillars, grades and DCF above.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where BSX and GMED diverge
On the headline score the gap is 1.1 points in favor of GMED. The widest single difference is Growth, where GMED leads by 5.0 points.
- GrowthBSX 88.4 · GMED 93.4GMED +5.0
- ValueBSX 75.8 · GMED 73.3level
- QualityBSX 71.2 · GMED 72.6level
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.